| Literature DB >> 21930178 |
Tomihisa Niitsu1, Yukihiko Shirayama, Daisuke Matsuzawa, Tadashi Hasegawa, Nobuhisa Kanahara, Tasuku Hashimoto, Tetsuya Shiraishi, Akihiro Shiina, Goro Fukami, Mihisa Fujisaki, Hiroyuki Watanabe, Michiko Nakazato, Makoto Asano, Sho Kimura, Kenji Hashimoto, Masaomi Iyo.
Abstract
Brain-derived neurotrophic factor (BDNF) may be involved in the pathophysiology of schizophrenia. The aim of this study was to examine the associations of serum BDNF levels with the cognition and clinical characteristics in patients with schizophrenia. Sixty-three patients with schizophrenia and 52 age- and sex-matched healthy controls were examined with neuropsychological tests. Serum BDNF levels were determined by enzyme-linked immunosorbent assay (ELISA). There were no significant differences in serum BDNF levels between normal controls and patients with schizophrenia. Serum BDNF levels of normal controls showed negative correlations with verbal working memory, but this was not the case with schizophrenic patients. Meanwhile, serum BDNF levels of schizophrenic patients showed positive correlations with the scores of the Scale for the Assessment of Negative Symptoms (SANS) and the Information subtest scores of Wechsler Adult Intelligence Scale Revised (WAIS-R). Serum BDNF levels are related with the impairment of verbal working memory and negative symptoms in patients with schizophrenia.Entities:
Mesh：
Substances：
Year: 2011 PMID： 21930178 DOI： 10.1016/j.pnpbp.2011.09.004
Source DB: PubMed Journal: Prog Neuropsychopharmacol Biol Psychiatry ISSN： 0278-5846 Impact factor: 5.067